2 results
Approved WMOCompleted
Primary objectiveTo evaluate if tralokinumab after 14 weeks of treatment (at steady state) changes the metabolism of substrates of CYP 1A2, 2C9, 2C19, 2D6, or 3A4 pathways in subjects with moderate-tosevere atopic dermatitisSecondary objectivesTo…
Approved WMOCompleted
This study aims to validate NI-fECG monitoring as an accurate and reliable monitoring technique for FHR, MHR and UA surveillance during labour. The aim of this validation is to work towards clinical implementation of NI-fECG monitoring.